Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Synovial Sarcoma Treatment Market
Synovial sarcoma refers to the abnormal growth of soft tissues. It is a rare type of cancer and is more prevalent among teenagers and young adults. Synovial sarcoma is highly metastatic and spreads to other places. In around 50% of the cases reported worldwide, lungs are found to be the most common site for the metastasis to occur. The principal cause behind the occurrence of synovial sarcoma has not yet been established; however, it is believed to be associated with abnormality in chromosome X and chromosome 18 in tumor cells.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/1571
Depending on the type of cells involved, it is classified into Monophasic and Biphasic, and poorly differentiated synovial sarcoma. Diagnosis of the synovial sarcoma involves imaging of the affected area, biopsy, genetic testing, and bone scans. Treatment of the synovial sarcoma involves a few approaches ranging from medication to surgery depending on the condition of the patient. For instance, surgery is considered if the tumor has clear margins and can be removed alongside healthy tissue. If a surgery is not possible then chemotherapy is opted which can kill cancerous, as well as healthy cells. Generally used chemotherapy drugs include ifosfamide, doxorubicin, and other drugs include dacarbazine, epirubicin, temozolomide, docetaxel, and gemcitabine. Moreover, radiotherapy may also be used alongside chemotherapy or as a standalone therapy. Some other therapies include angiogenesis inhibitors, which can prevent growth of tumor, and biological therapies to boost patient’s immunity system to fight against cancer. The treatment options highly depend on individual condition of the patients, as there is no standard treatment for it.
Global Synovial Sarcoma Treatment Market Insights
As estimated by the American Cancer Society, the incidence of synovial sarcoma in the U.S. for 2018 is expected to be 13,040 patients out of which 7,370 in males and 5,670 in females. Extensive research & development in this field for the development of innovative therapies for the treatment of synovial sarcoma is expected to boost the global synovial sarcoma treatment market growth over the forecast period. For instance, organizations such as Accuronix Therapeutics, Advenchen Laboratories, LLC, Immune Design, Cue Biopharma, and others, are working on the research and development of novel immunotherapy candidates for the treatment of synovial sarcoma. Accuronix Therapeutics has ACXT-3102, a small molecule drug conjugate, in preclinical development for treatment of synovial sarcoma and other cancers. Advanchen Laboratories has AL3818 (anlotinib) in Phase 3 clinical trials for the treatment of synovial sarcoma (SS), and other indications. Moreover, Immune Design has an antigen-specific prime boost CMB305 in Phase 2 clinical trials for synovial sarcoma. Cue Biopharma is working on CUE-102, a potential treatment for melanoma, synovial sarcoma, prostate, and head and neck cancers.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1571
In 2016, Adaptimmune Therapeutics received the T-Cell therapy breakthrough designation by the U.S. Food & Drug Administration (FDA) for its NY-ESO-1 T-cell therapy. Furthermore, Immunocore, a U.K.-based biotechnology company, is currently working on the development of ImmTAC (Immune mobilizing monoclonal TCRs), which has potential applications in various cancers, including synovial sarcoma.
Moreover, exclusive research on novel vaccines for the treatment of synovial sarcoma is underway, which could potentially increase the treatment options for synovial sarcoma. These factors are expected to boost growth of the synovial sarcoma treatment market over the forecast period. However, the side effects associated with cancer treatment, high costs, and uncertainty of the results of clinical trials are significant factors expected to affect the global market growth negatively during the forecast period.
Global Synovial Sarcoma Treatment Market – Regional Insights
North America is expected to witness significant growth over the forecast period, due to research and development, and high prevalence of the synovial sarcoma. Immunotherapy is a popular treatment in the region, wherein, application of immunotherapies such as checkpoint-inhibitors and adoptive T cell therapy is being researched for the treatment of synovial sarcoma. Another approach that is being studied, is the combination therapy including two or more immunotherapy candidates, which have shown potential effects in the synovial sarcoma treatment. For instance, positive results of phase 2 studies of the combination of Axitinib and Pembrolizumab in the treatment of advanced alveolar soft part sarcoma and other soft tissue sarcomas were presented at Connective Tissue Oncology Society Annual Meeting in 2017.
Moreover, the market in Europe is poised to witness immense growth, owing to presence of innovative biotech companies such as Immunocore, which are actively involved in research and development of targeted therapies, such as ImmTAC.
Global Synovial Sarcoma Treatment Market – Competitive Outlook
The renowned players operating in the global synovial sarcoma treatment market include Pfizer, Inc., Eli Lilly and Company, Genentech USA, F. Hoffmann-La Roche Ltd, Johnson & Johnson, GlaxoSmithKline, Bristol-Myers Squibb, Teva Pharmaceuticals, and Celgene Corporation.
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1571
Global Synovial Sarcoma Treatment Market Taxonomy
By Treatment Type
- Chemotherapy
- Anti-Angiogenesis Drugs
- Radiotherapy
- Others
By End-User
- Hospitals
- Oncology Centers
- Others
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837